Clinical Trial Update: An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors [Phase 1]

View source ↗

Summary

Completed Phase 1 ADME study evaluating pharmacokinetics of a single oral dose of [14C] GSK2118436 (dabrafenib) in patients with BRAF-mutant solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• GSK2118436 (dabrafenib) (dabrafenib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: COMPLETED